{"id":"3894bed6-e26d-4cf5-8580-e480d5f8fb27","arxiv_id":"2607.06133","paper_version":1,"verdict":"CONDITIONAL","confidence":"MODERATE","novelty_score":4.0,"correctness_risk":"unknown","formal_verification":"none","parameter_count":0,"one_line_summary":"Synthetic data generation in privacy-constrained medical domains shifts the engineering challenge from data availability to the elicitation, validation, and evolution of stakeholder-specific validity properties.","lead":"This paper argues that synthetic data generation in data-scarce domains like medicine is not just a preprocessing step but a software engineering problem requiring explicit, stakeholder-specific validity properties. A smart generalist might read it to understand the non-obvious gap between generating statistically plausible data and data that is clinically, legally, and practically useful.","discovery_kind":"unclear","skeptic_critique":{"model":"glm-5.2","headline":"Paper's central SE-gap claim is undermined by its own cited prior work: Zazzetti et al. [18] already provides a multi-property validation framework (SAFE) for synthetic breast cancer data covering fidelity, privacy, and clinical utility, and the paper never specifies what SE-specific contributiongoe","rationale":"The reader identified the correct load-bearing concern: the paper's novelty as a distinct SE paradigm depends on whether property-driven validation of synthetic data is genuinely new relative to existing requirements engineering and medical informatics practices. My analysis confirms this and sharpens it: the paper's own cited prior work (Zazzetti et al. [18], SAFE framework) already covers multi-property validation (fidelity, privacy, clinical utility) for synthetic breast cancer data, and the paper does not articulate a specific technical gap that would justify a new SE research agenda. The formalization in Figure 1 is a straightforward restatement of 'synthetic data should satisfy stakeholder properties,' and the lessons L1–L4 are well-known observations. The verdict of CONDITIONAL is appropriate: the paper is a reasonable reflection piece with a useful framing, but its contribution is incremental rather than paradigm-shifting. The confidence level of MODERATE is also appropriate given that this is a position paper without formal verification or extensive empirical validation. I recommend UNCHANGED because the reader's assessment already captures this concern accurately, and my analysis does not reveal a more fundamental technical flaw beyond the novelty gap. The paper is internally consistent — it does not make contradictory claims — and its preliminary experiments, while basic, are not misrepresented. The issue is one of contribution strength, not correctness.","tokens_in":8523,"tokens_out":1769,"duration_ms":113382,"concrete_test":"Construct a feature comparison table between the paper's proposed property-driven agenda (Table 1: constraint mining, rule checking, metric selection, privacy risk analysis, drift detection, impact analysis) and existing frameworks like SAFE [18] and the benchmarking approach of Yan et al. [17]. For each automation opportunity in Table 1, mark whether it is already implemented, partially addressed, or genuinely absent in existing work. If more than 50% of the automation opportunities are already addressed by existing frameworks, the paper's claim of an unaddressed SE gap weakens significantly.","verdict_should_be":"UNCHANGED","load_bearing_attack":"The paper's central claim is that SDG introduces an unaddressed SE problem: stakeholders must define, trade off, and evolve validity properties, and 'current methodologies do not adequately support or address' these trade-offs (Section 6). Yet the paper itself cites Zazzetti et al. [18], which proposes the SAFE framework for synthetic breast cancer data that already assesses fidelity, privacy, and clinical utility — the exact multi-property validation space the paper claims is unaddressed. The paper's formalization (Figure 1, Section 2) is a restatement of this: D' should satisfy properties P. The lessons (L1–L4) — data cleaning matters, validity is multi-property, no universal best generator, pipelines evolve — are standard observations already discussed in the synthetic data and medical informatics literature. The paper does not identify a specific technical gap between existing frameworks like SAFE and what it proposes. For instance, it does not point to a concrete operation that SAFE cannot perform (e.g., automated property conflict detection, cross-stakeholder trade-off resolution, or pipeline evolution monitoring) that would require new SE methods. Without this gap analysis, the claim that there is a distinct SE research agenda beyond what medical informatics already does is unsupported. The reader correctly identified this as the weakest assumption; the concern is specifically that the paper's own related work section undercuts its novelty claim rather than establishing the gap.","agreement_with_reader":"agree"},"referee_report":{"model":"glm-5.2","summary":"This paper proposes framing synthetic data generation (SDG) in data-scarce, privacy-constrained software systems as a property-driven engineering problem. Using a breast cancer intraoperative radiotherapy (IORT) case study, the authors argue that SDG shifts rather than solves the central engineering challenge: the key difficulty becomes eliciting, formalizing, checking, and evolving stakeholder-specific validity properties (e.g., statistical fidelity, clinical plausibility, privacy protection, task utility) rather than merely generating statistically similar data. The paper reports preliminary experiments with five tabular SDG techniques on a 709-patient dataset, identifies four lessons (L1–L4), and outlines a research agenda for automated software engineering support. The paper is positioned as a reflection and agenda-setting piece, not as a method validation or empirical benchmark.","tokens_in":8914,"tokens_out":1322,"duration_ms":273465,"significance":"The paper addresses a timely and practically important problem at the intersection of software engineering and medical informatics. Its central observation—that synthetic data validity is inherently multi-property, stakeholder-dependent, and potentially conflicting—is well-motivated and illustrated with a real clinical collaboration. The mapping in Table 1 connecting stakeholders to properties, checks, and automation opportunities is a useful concrete artifact that could guide future tool development. The preliminary experiments, while not claiming clinical validity, effectively demonstrate the gap between statistical plausibility and clinical validity. However, the paper's novelty claim rests on the assertion that this constitutes a distinct SE research agenda, and this claim is not yet sufficiently differentiated from existing work in the medical informatics and synthetic data validation literature. The paper does not ship reproducible code or machine-checked artifacts, which is expected for a reflection piece but limits verifiability.","major_comments":[{"comment":"§5 (Related Work) and §6 (Conclusion): The paper's central novelty claim is that SDG introduces an SE problem not adequately addressed by current methodologies, specifically that stakeholders must define, trade off, and evolve validity properties. However, the paper itself cites Zazzetti et al. [18], which proposes the SAFE framework for synthetic breast cancer data that already assesses fidelity, privacy, and clinical utility — the exact multi-property validation space the paper claims is unaddressed. The paper does not specify what concrete technical capability is missing from SAFE and similar frameworks (e.g., automated property conflict detection, cross-stakeholder trade-off resolution, pipeline evolution monitoring) that would require new SE methods. Without this gap analysis, the claim that there is a distinct SE research agenda beyond what medical informatics already provides is a","section":null},{"comment":"§4, Table 1: The mapping of stakeholders to properties, checks, and automation opportunities is the most concrete contribution, but the automation opportunities listed (e.g., 'constraint mining,' 'rule checking,' 'property-based test generation,' 'drift detection') are presented at a very high level without connecting to the state of the art in each sub-area. For the agenda to be actionable, the paper should identify which of these automation opportunities are genuinely open problems versus which could be addressed by adapting existing SE techniques (e.g., property-based testing, invariant mining, requirements monitoring). As it stands, it is unclear whether the research agenda requires fundamentally new SE methods or routine application of existing ones to a new domain.","section":null},{"comment":"§3 (Preliminary Experimentation): The experimental results are used to motivate the research agenda but lack quantitative detail. The paper states that TVAE achieved better results than other approaches based on correlation matrix similarity (Figure 2) and Kaplan-Meier curve comparison, but no quantitative metrics are reported (e.g., correlation distance, KS test statistics, log-rank test p-values). Without at least summary metrics, the reader cannot assess whether the claimed differences between generators are meaningful or whether the observed statistical plausibility vs. clinical validity gap is substantive. This weakens the empirical grounding for the lessons L2 and L3.","section":null}],"minor_comments":[{"comment":"§2, Figure 1: The notation in the figure (D, A(D), R, D', A(D'), R', f, P) is introduced in the text but the figure itself lacks labels or a caption explaining the symbols. Adding a brief caption would improve readability.","section":null},{"comment":"§3, Dataset Cleaning: The threshold of 80% missing values for column removal is stated without justification. A brief note on why this threshold was chosen (or whether it was validated with oncologists) would strengthen the discussion.","section":null},{"comment":"§3: The paper mentions that 'some differences appeared at the end of the curves, where the number of patients was low' but does not report the sample sizes at the tail of the Kaplan-Meier curves. Including this information would help readers assess the reliability of the comparison.","section":null},{"comment":"§4, L1: The lesson title 'Data cleaning is engineering, not pre-processing' is somewhat overstated relative to the supporting argument, which is that cleaning decisions affect downstream property satisfiability. Consider softening to 'Data cleaning is a specification activity, not mere pre-processing.'","section":null},{"comment":"§5: The related work section is brief and could benefit from citing and positioning against requirements engineering approaches for data-intensive systems and data quality frameworks, which are directly relevant to the property-driven framing.","section":null},{"comment":"§1: 'a software system that that supports' — duplicate 'that.'","section":null},{"comment":"§6: 'current methodologies do not adequately support or address' is a strong claim that should either be softened or supported with specific examples of what existing methodologies fail to address.","section":null}],"recommendation":"major_revision","confidential_remarks":"The paper is a well-written reflection piece from a credible collaboration, and the IORT domain provides a compelling motivating example. However, the novelty claim is the load-bearing issue: the paper needs to clearly distinguish its SE research agenda from existing multi-property validation frameworks like SAFE [18], which the authors themselves cite. If the authors can articulate a concrete technical gap (e.g., automated conflict detection between stakeholder properties, formal property evolution mechanisms) that existing medical informatics work does not address, the paper could make a strong agenda-setting contribution. Without that, it risks being perceived as a domain application of known ideas. I lean toward major revision rather than reject because the framing is genuinely interesting and the collaboration gives the work authenticity, but the gap analysis is essential for the contribution to land."},"author_rebuttal":{"model":"glm-5.2","summary":"We thank the referee for a careful and constructive review. The referee's three major comments are all well-taken, and we will address each in a revised manuscript. Below we respond point by point.","responses":[{"response":"The referee is correct that our current draft does not adequately differentiate our research agenda from SAFE and similar validation frameworks. We will revise §5 to provide a concrete gap analysis. To preview the argument: SAFE and comparable frameworks (e.g., the benchmarking approach of Yan et al. [17]) provide post-hoc validation pipelines — they evaluate generated data against a fixed set of metrics (fidelity, privacy, utility) after generation. What they do not provide are SE capabilities for: (1) automated elicitation and formalization of stakeholder-specific validity properties from informal clinical requirements, (2) detection and resolution of conflicts between properties across stakeholders (e.g., when privacy constraints conflict with clinical plausibility requirements), (3) property-driven generator selection and configuration — i.e., reasoning about which generator satisfies which properties rather than evaluating all generators post-hoc, and (4) continuous monitoring and evolution of property satisfaction as real data, clinical guidelines, and stakeholder needs change over time. SAFE treats validation as a fixed checklist; our agenda treats it as an evolving, stakeholder-driven engineering process. We will make this distinction explicit in the revised §5 and adjust the novelty claim in §6 accordingly, acknowledging that validation frameworks like SAFE exist while arguing that the SE challenges of property elicitation, conflict resolution, and pipeline evolution are not addressed by them.","revision_made":"yes","referee_comment":"§5/§6: The paper cites Zazzetti et al. [18] (SAFE), which already assesses fidelity, privacy, and clinical utility — the exact multi-property validation space the paper claims is unaddressed. The paper does not specify what concrete technical capability is missing from SAFE and similar frameworks that would require new SE methods."},{"response":"This is a fair criticism. In the revision, we will add a paragraph (or an expanded table) that maps each automation opportunity to the relevant SE sub-field and assesses the gap. Concretely: (a) 'Constraint mining' and 'rule checking' connect to invariant mining and specification mining (e.g., Daikon-style dynamic invariant detection, association rule mining); these are partially adaptable but have not been applied to clinical plausibility constraints for synthetic data, where constraints are domain-specific and may involve temporal/sequential plausibility — a genuine gap. (b) 'Property-based test generation' connects to existing PBT frameworks (e.g., QuickCheck, Hypothesis); adapting these to synthetic data validation is largely an engineering effort, though defining meaningful property oracles for clinical validity remains open. (c) 'Drift detection' and 'impact analysis' connect to requirements monitoring and runtime verification (e.g., RV techniques); existing methods can detect distributional drift but do not reason about whether drift invalidates specific stakeholder properties — an open problem. (d) 'Privacy risk analysis' is an active area in the security/privacy community (membership inference, distance-based disclosure metrics) but is typically treated in isolation from clinical and utility properties, making cross-property trade-off analysis an open SE challenge. We will incorporate this analysis to make the agenda actionable and to honestly distinguish novel SE challenges from routine application of existing techniques.","revision_made":"yes","referee_comment":"§4, Table 1: The automation opportunities are presented at a very high level without connecting to the state of the art. The paper should identify which are genuinely open problems versus which could be addressed by adapting existing SE techniques."},{"response":"The referee is right that the current draft relies on visual comparison (Figure 2, correlation matrix inspection) without reporting quantitative metrics. We will add a summary table reporting, for each generator: (1) Frobenius norm distance between the correlation matrices of real and synthetic data, (2) column-wise KS test statistics (median and range across variables), (3) log-rank test p-values for the Kaplan-Meier curve comparisons (global and stratified), and (4) concordance index (C-index) for the univariate and multivariate Cox models fitted on real vs. synthetic data. We agree that without these metrics, the reader cannot assess whether the differences between generators are meaningful or whether the statistical-plausibility-vs-clinical-validity gap is substantive. Adding these metrics will also strengthen the empirical grounding for L2 and L3. We note that, as stated in the paper, we do not claim clinical validity for any generator; the quantitative metrics will support the more limited claim that generators can appear statistically plausible while requiring domain-specific validation.","revision_made":"yes","referee_comment":"§3: Experimental results lack quantitative detail. No correlation distance, KS test statistics, log-rank test p-values, or other summary metrics are reported."}],"tokens_in":8390,"tokens_out":1316,"duration_ms":91801,"standing_objections":[]},"desk_editor":{"model":"glm-5.2","letter":"Short version: this is a well-written reflection piece that frames synthetic data generation (SDG) in data-scarce domains as a software engineering problem — not just an ML preprocessing step. The core observation is that SDG shifts the engineering burden from data availability to property elicitation, validation, and evolution. The framing is useful and the case study is real. But the paper's novelty claim is narrower than it asserts, and the stress-test concern about Zazzetti et al. [18] lands squarely. The paper deserves a serious referee, but the referee should push the authors to sharpen what is genuinely SE-specific here. What is actually new: the synthesis of SDG challenges into an explicit SE research agenda with a stakeholder-to-property-to-automation mapping (Table 1). Table 1 is the most concrete artifact — it links stakeholders (clinicians, data scientists, privacy officers, software engineers, maintainers) to specific properties, checks, and automation opportunities. That mapping is a genuine contribution for the SE community, even if the individual observations are not new. The IORT case study is authentic: real hospital collaboration, real dataset (1000 patients, 64 variables), real cleaning decisions, real comparison of five generators with Kaplan-Meier and Cox model validation. The paper is honest about its limitations — it explicitly states it does not claim clinical validity for the synthetic data. The soft spot is real and load-bearing. The paper claims current methodologies 'do not adequately support or address' multi-property trade-offs in SDG (Section 6), but it cites Zazzetti et al. [18], which proposes the SAFE framework covering fidelity, privacy, and clinical utility for synthetic breast cancer data — exactly the multi-property validation space this paper claims is unaddressed. The paper never identifies a concrete technical operation that SAFE cannot perform. It does not point to a specific gap in automated property conflict detection, cross-stakeholder trade-off resolution, or pipeline evolution monitoring that would require new SE methods beyond what medical informatics already does. The lessons (L1–L4) are standard observations: data cleaning matters, validity is multi-property, no universal best generator, pipelines evolve. These are true but not novel. The formalization in Figure 1 (D' should satisfy properties P) is a restatement of existing SDG validation frameworks, not a new formal model. The stress-test concern is correct on this point. The reader's assessment (CONDITIONAL, MODERATE confidence) is fair. The significance-if-true score of 4.0 is slightly generous — the paper sets an agenda but does not introduce new methods, tools, or formalisms that would immediately change practice. Who this is for: SE researchers working at the intersection of requirements engineering, testing, and data-driven systems who want a problem statement to orient future work. Medical informatics researchers will find little new. It deserves a serious referee who should ask the authors to either (a) identify a concrete technical gap between existing frameworks like SAFE and what they propose, or (b) reframe the contribution as an SE perspective on an existing problem rather than a new research agenda. As-is, it is a solid reflection with an overstated novelty claim.","headline":"Agenda-setting reflection on synthetic data as an SE problem; the central novelty claim is undercut by its own cited prior work.","tokens_in":9469,"tokens_out":717,"would_cite":false,"duration_ms":88357,"reading_group":"no","serious_thinker":"no","would_accept_peer_review":true},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"glm-5.2","headline":"Synthetic data shifts the problem, not solves it","keywords":["synthetic data generation","property-driven engineering","data scarcity","software engineering","breast cancer","IORT","requirements engineering","validation"],"falsifier":"If synthetic data generators could be shown to automatically satisfy all stakeholder-relevant properties without explicit elicitation or trade-off — for instance, through sufficiently advanced generation techniques that preserve clinical constraints, statistical distributions, and privacy simultaneously — then the property-driven engineering process would reduce to generator selection, undermining the paper's central claim.","tokens_in":8620,"feed_emoji":"🔬","tokens_out":1247,"duration_ms":62349,"temperature":0.7,"pith_summary":"This paper argues that synthetic data generation, widely proposed as a fix for data-scarce software systems, does not eliminate the core engineering challenge but relocates it. Drawing on a collaboration with oncologists and preliminary experiments with an intraoperative radiotherapy (IORT) breast cancer dataset, the authors show that a synthetic dataset can be statistically similar to the original yet clinically implausible. The real difficulty, they contend, is determining which properties synthetic data must preserve, eliciting those properties from different stakeholders (clinicians, data scientists, privacy officers, software engineers), validating them without reliable ground truth, and maintaining them as data and requirements evolve. They call this problem property-driven synthetic data engineering and frame it as a new software engineering research agenda in which the central artifacts are not datasets or generators but stakeholder-specific validity properties that must be explicitly traded off against each other.","feed_headline":"Synthetic data shifts the problem, not solves it","feed_subtitle":"A breast cancer case study shows that generating fake data is easy; deciding what it must preserve is the real software engineering problem.","key_machinery":"The central object is the property set P — stakeholder-specific validity properties that synthetic data must satisfy — and the engineering lifecycle around it: elicitation, formalization, checking, trade-off analysis, and evolution. The paper also introduces a stakeholder-to-property mapping (Table 1) that connects different roles to their desired properties, example checks, and automation opportunities.","core_discovery":"The paper's central claim is that synthetic data generation in data-scarce domains is fundamentally a software engineering problem, not a data preprocessing step. The authors formalize this by defining synthetic data generation as producing a dataset D' that, when processed by an analysis A, yields results R' that must satisfy a set of properties P. These properties are stakeholder-dependent and potentially conflicting: a clinician needs clinical plausibility, a data scientist needs statistical fidelity, a privacy officer needs disclosure protection, and a software engineer needs test adequacy. The paper demonstrates through its IORT case study that different generators (CTGAN, TVAE, TabDDPM","pith_inferences":["The paper's framing implies that existing requirements engineering techniques (e.g., goal-oriented modeling, conflict detection) could be adapted to elicit and resolve property conflicts in synthetic data pipelines, though the paper does not make this connection explicit.","The stakeholder-to-property mapping in Table 1 suggests a formalization where each property could be encoded as a constraint or specification, enabling automated verification — but the paper stops short of proposing a concrete specification language.","The observation that statistical similarity does not imply clinical validity hints at a deeper separation between distributional fidelity and semantic fidelity that could apply to any domain where synthetic data must satisfy domain-specific constraints.","The evolution challenge implies a need for versioned property specifications tied to data versions, analogous to how software specifications are versioned alongside code — a direction the paper gestures toward but does not develop."],"forward_implications":["If the paper is right, then selecting a synthetic data generator is not an ML model-selection problem but a requirements engineering problem: the choice depends on which stakeholder properties matter for the target task, not on aggregate similarity metrics.","If validity is inherently multi-property and properties conflict, then synthetic data pipelines need explicit trade-off mechanisms — analogous to multi-objective optimization — rather than single-metric evaluation.","If data cleaning decisions determine which properties can later be synthesized and validated, then data cleaning becomes part of the system specification, not a disposable preprocessing step.","If synthetic data pipelines must evolve as populations, treatments, and regulations change, then continuous monitoring and drift detection of validity properties become a maintenance concern comparable to software regression testing.","If the property-driven framing generalizes beyond medicine, then any data-scarce, privacy-constrained domain (e.g., safety-critical systems, regulated industries) faces the same shift from data-driven to property-driven validation."],"fun_headline_variants":["Synthetic data shifts the engineering burden to property validation","The hard part of synthetic data is defining what it must preserve","Generating fake data is easy; eliciting its constraints is the real problem","In data-scarce systems, synthetic data is a requirements engineering problem","Synthetic data moves the data scarcity problem to stakeholder property checks"],"cache_read_input_tokens":0,"weakest_assumption_plain":"The paper assumes that framing synthetic data validation as a property-driven software engineering problem constitutes a new research paradigm, rather than an application of existing requirements engineering and data validation practices to a new artifact type. If property-driven validation of synthetic data turns out to be routine requirements engineering applied to synthetic datasets, the paper's contribution narrows from a new paradigm to a domain-specific case study.","fun_headline_variants_meta":{"raw":{"variants":["Synthetic data shifts the engineering burden to property validation","The hard part of synthetic data is defining what it must preserve","Generating fake data is easy; eliciting its constraints is the real problem","In data-scarce systems, synthetic data is a requirements engineering problem","Synthetic data moves the data scarcity problem to stakeholder property checks"]},"model":"glm-5.2","effort":"high","cost_usd":0.0,"raw_usage":{"total_tokens":1293,"prompt_tokens":495,"completion_tokens":798,"prompt_tokens_details":null},"tokens_in":495,"tokens_out":798,"duration_ms":43323,"temperature":1.0,"reasoning_tokens":745,"cache_read_input_tokens":0,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-07-08T15:28:22.747085+00:00","model_set":{"reader":"glm-5.2"},"falsifier":"If synthetic data generators could be shown to automatically satisfy all stakeholder-relevant properties without explicit elicitation or trade-off — for instance, through sufficiently advanced generation techniques that preserve clinical constraints, statistical distributions, and privacy simultaneously — then the property-driven engineering process would reduce to generator selection, undermining the paper's central claim.","supporting_citations":[],"review_version":1}